Talphera, Inc. — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 1.03 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 53.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Details
| Name | Talphera, Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 12 |
| Founded | 2005 |
| Ipo Date | 2011-02-14 |
| Ceo | Vincent Angotti |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US00444T2096 |
| Cusip | 00444T209 |
| Cik | 0001427925 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Vincent J. Angotti | Chief Executive Officer and Director |
| Raffi Mark Asadorian | Chief Financial Officer |
| Dr. Shakil Aslam M.D. | Chief Medical Officer |
| Anil N. Dasu | Chief Engineering Officer |
Contact
| Address | 1850 Gateway Drive, Suite 175, San Mateo, California 94404, United States |
| Phone | 650 216 3500 |
| Website | https://talphera.com |